Industry News

Zanubrutinib is a novel BTK (Bruton's tyrosine kinase) inhibitor independently developed by BeiGene in China. It belongs to the small-molecule targeted anti-tumor drug category.

Carfilzomib is a targeted anti-tumor drug, belonging to the class of irreversible proteasome inhibitors, primarily used to treat relapsed or refractory multiple myeloma (RRMM).

Upatinib is an orally administered, highly selective JAK1 inhibitor, a small-molecule targeted therapy primarily used to treat various immune-mediated chronic inflammatory diseases.